Kaposi's Sarcoma Associated Herpesvirus Tegument Protein ORF75 Is Essential for Viral Lytic Replication and Plays a Critical Role in the Antagonization of ND10-Instituted Intrinsic Immunity

English version České info

Nuclear domain 10 (ND10) components are restriction factors that inhibit herpesviral replication. Effector proteins of different herpesviruses can antagonize this restriction by a variety of strategies, including degradation or relocalization of ND10 proteins. We investigated the interplay of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) infection and cellular defense by nuclear domain 10 (ND10) components. Knock-down experiments in primary human cells show that KSHV-infection is restricted by the ND10 components PML and Sp100, but not by ATRX. After KSHV infection, ATRX is efficiently depleted and Daxx is dispersed from ND10, indicating that these two ND10 components can be antagonized by KSHV. We then identified the ORF75 tegument protein of KSHV as the viral factor that induces the disappearance of ATRX and relocalization of Daxx. ORF75 belongs to a viral protein family (viral FGARATs) that has homologous proteins in all gamma-herpesviruses. Isolated expression of ORF75 in primary cells induces a relocalization of PML and dispersal of Sp100, indicating that this viral effector protein is able to influence multiple ND10 components. Moreover, by constructing a KSHV mutant harboring a stop codon at the beginning of ORF75, we could demonstrate that ORF75 is absolutely essential for viral replication and the initiation of viral immediate-early gene expression. Using recombinant viruses either carrying Flag- or YFP-tagged variants of ORF75, we could further corroborate the role of ORF75 in the antagonization of ND10-mediated intrinsic immunity, and show that it is independent of the PML antagonist vIRF3. Members of the viral FGARAT family target different ND10 components, suggesting that the ND10 targets of viral FGARAT proteins have diversified during evolution. We assume that overcoming ND10 intrinsic defense constitutes a critical event in the replication of all herpesviruses; on the other hand, restriction of herpesviral replication by ND10 components may also promote latency as the default outcome of infection.

Vyšlo v časopise: Kaposi's Sarcoma Associated Herpesvirus Tegument Protein ORF75 Is Essential for Viral Lytic Replication and Plays a Critical Role in the Antagonization of ND10-Instituted Intrinsic Immunity. PLoS Pathog 10(1): e32767. doi:10.1371/journal.ppat.1003863
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1003863

Souhrn

Zdroje

1. ChangY, CesarmanE, PessinMS, LeeF, CulpepperJ, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865–1869.

2. DupinN, GrandadamM, CalvezV, GorinI, AubinJT, et al. (1995) Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 345: 761–762.

3. GanemD (2010) KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 120: 939–949.

4. TavalaiN, StammingerT (2008) New insights into the role of the subnuclear structure ND10 for viral infection. Biochim Biophys Acta 1783: 2207–2221.

5. MaulGG, GuldnerHH, SpivackJG (1993) Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J Gen Virol 74 (Pt 12) 2679–2690.

6. BoutellC, SadisS, EverettRD (2002) Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J Virol 76: 841–850.

7. BoutellC, Cuchet-LourencoD, VanniE, OrrA, GlassM, et al. (2011) A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog 7: e1002245.

8. LeeHR, KimDJ, LeeJM, ChoiCY, AhnBY, et al. (2004) Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J Virol 78: 6527–6542.

9. MullerS, DejeanA (1999) Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J Virol 73: 5137–5143.

10. Chelbi-AlixMK, PelicanoL, QuignonF, KokenMH, VenturiniL, et al. (1995) Induction of the PML protein by interferons in normal and APL cells. Leukemia 9: 2027–2033.

11. GrotzingerT, SternsdorfT, JensenK, WillH (1996) Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Eur J Biochem 238: 554–560.

12. KatanoH, Ogawa-GotoK, HasegawaH, KurataT, SataT (2001) Human-herpesvirus-8-encoded K8 protein colocalizes with the promyelocytic leukemia protein (PML) bodies and recruits p53 to the PML bodies. Virology 286: 446–455.

13. Marcos-VillarL, Lopitz-OtsoaF, GallegoP, Munoz-FontelaC, Gonzalez-SantamariaJ, et al. (2009) Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol 83: 8849–8858.

14. ChangPC, IzumiyaY, WuCY, FitzgeraldLD, CampbellM, et al. (2010) Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J Biol Chem 285: 5266–5273.

15. WuFY, AhnJH, AlcendorDJ, JangWJ, XiaoJ, et al. (2001) Origin-independent assembly of Kaposi's sarcoma-associated herpesvirus DNA replication compartments in transient cotransfection assays and association with the ORF-K8 protein and cellular PML. J Virol 75: 1487–1506.

16. FullF, ReuterN, ZielkeK, StammingerT, EnsserA (2012) Herpesvirus Saimiri Antagonizes Nuclear Domain 10-Instituted Intrinsic Immunity via an ORF3-Mediated Selective Degradation of Cellular Protein Sp100. J Virol 86: 3541–3553.

17. LingPD, TanJ, SewatanonJ, PengR (2008) Murine gammaherpesvirus 68 open reading frame 75c tegument protein induces the degradation of PML and is essential for production of infectious virus. J Virol 82: 8000–8012.

18. TsaiK, ThikmyanovaN, WojcechowskyjJA, DelecluseHJ, LiebermanPM (2011) EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog 7: e1002376.

19. KonradA, WiesE, ThurauM, MarquardtG, NaschbergerE, et al. (2009) A systems biology approach to identify the combination effects of human herpesvirus 8 genes on NF-kappaB activation. J Virol 83: 2563–2574.

20. VieiraJ, O'HearnPM (2004) Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology 325: 225–240.

21. MyoungJ, GanemD (2011) Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J Virol Methods 174: 12–21.

22. StürzlM, GausD, DirksWG, GanemD, JochmannR (2013) Kaposi's sarcoma-derived cell line SLK is not of endothelial origin, but is a contaminant from a known renal carcinoma cell line. Int J Cancer 132: 1954–1958.

23. BechtelJT, WinantRC, GanemD (2005) Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. J Virol 79: 4952–4964.

24. RozenR, SathishN, LiY, YuanY (2008) Virion-wide protein interactions of Kaposi's sarcoma-associated herpesvirus. J Virol 82: 4742–4750.

25. BruloisKF, ChangH, LeeAS, EnsserA, WongLY, et al. (2012) Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome clone. J Virol 86: 9708–9720.

26. GasparM, GillMB, LosingJB, MayJS, StevensonPG (2008) Multiple functions for ORF75c in murid herpesvirus-4 infection. PLoS ONE 3: e2781.

27. GüntherT, GrundhoffA (2010) The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathog 6: e1000935.

28. TothZ, MaglinteDT, LeeSH, LeeHR, WongLY, et al. (2010) Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog 6: e1001013.

29. Marcos-VillarL, CampagnaM, Lopitz-OtsoaF, GallegoP, Gonzalez-SantamariaJ, et al. (2011) Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi's sarcoma-associated herpesvirus latent protein LANA2. J Gen Virol 92: 188–194.

30. JooCH, ShinYC, GackM, WuL, LevyD, et al. (2007) Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J Virol 81: 8282–8292.

31. JacobsSR, DamaniaB (2011) The viral interferon regulatory factors of KSHV: immunosuppressors or oncogenes? Front Immunol 2: 19.

32. SchmidtK, WiesE, NeipelF (2011) Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression. J Virol 85: 4530–4537.

33. OrensteinJM, AlkanS, BlauveltA, JeangKT, WeinsteinMD, et al. (1997) Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. AIDS 11: F35–F45.

34. StaskusKA, ZhongW, GebhardK, HerndierB, WangH, et al. (1997) Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71: 715–719.

35. GrundhoffA, GanemD (2004) Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113: 124–136.

36. MartinDF, KuppermannBD, WolitzRA, PalestineAG, LiH, et al. (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340: 1063–1070.

37. JahnG, KnustE, SchmollaH, SarreT, NelsonJA, et al. (1984) Predominant immediate-early transcripts of human cytomegalovirus AD 169. J Virol 49: 363–370.

38. AdlerM, TavalaiN, MüllerR, StammingerT (2011) Human cytomegalovirus immediate-early gene expression is restricted by the nuclear domain 10 component Sp100. J Gen Virol 92: 1532–1538.

39. TavalaiN, PapiorP, RechterS, LeisM, StammingerT (2006) Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J Virol 80: 8006–8018.

40. TavalaiN, AdlerM, SchererM, RiedlY, StammingerT (2011) Evidence for a dual antiviral role of the major nuclear domain 10 component Sp100 during the immediate-early and late phases of the human cytomegalovirus replication cycle. J Virol 85: 9447–9458.

41. TischerBK, von EinemJ, KauferB, OsterriederN (2006) Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40: 191–197.

42. TischerBK, SmithGA, OsterriederN (2010) En passant mutagenesis: a two step markerless red recombination system. Methods Mol Biol 634: 421–430.

43. ZhangY, BuchholzF, MuyrersJP, StewartAF (1998) A new logic for DNA engineering using recombination in Escherichia coli. Nat Genet 20: 123–128.

44. SchindelinJ, Arganda-CarrerasI, FriseE, KaynigV, LongairM, et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9: 676–682.